ursodeoxycholic acid has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bertoldo, M; Bovolenta, M; Capobianco, ML; Mamchaoui, K; Marchesi, E; Perrone, D; Preti, L | 1 |
Berge, J; Bledsoe, C; Carlson, CG; Gatti, F; Lavin, J; Millman, G; Palmeiri, B; Rutter, J; Siegel, AL; Turin, E; Winders, WT | 1 |
2 other study(ies) available for ursodeoxycholic acid and Muscular Dystrophy, Duchenne
Article | Year |
---|---|
Synthesis and Exon-Skipping Properties of a 3'-Ursodeoxycholic Acid-Conjugated Oligonucleotide Targeting
Topics: Cell Line, Transformed; Exons; Humans; Muscular Dystrophy, Duchenne; Myoblasts, Skeletal; Oligonucleotides, Antisense; RNA Precursors; Ursodeoxycholic Acid | 2021 |
Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Disease Models, Animal; Female; Male; Mice; Mice, Inbred mdx; Muscle Strength; Muscle Stretching Exercises; Muscle Tonus; Muscle Weakness; Muscle, Skeletal; Muscular Dystrophy, Duchenne; NF-kappa B; Pyrrolidines; Recovery of Function; Thiocarbamates; Transcription Factor RelA; Treatment Outcome; Ursodeoxycholic Acid | 2009 |